<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39221179</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1362</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vaccine: X</Title><ISOAbbreviation>Vaccine X</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.</ArticleTitle><Pagination><StartPage>100546</StartPage><MedlinePgn>100546</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100546</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvacx.2024.100546</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Health care workers (HCWs) have been at increased risk of infection during the SARS-CoV-2 pandemic and as essential workers have been prioritised for vaccination. Due to increased exposure HCW are considered a predictor of what might happen in the general population, particularly working age adults. This study aims to summarise effect of vaccination in this 'at risk' cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Ovid MEDLINE and Embase were searched, and 358 individual articles were identified. Of these 49 met the inclusion criteria for review and 14 were included in a meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Participants included were predominantly female and working age. Median time to infection was 51&#xa0;days. Reported vaccine effectiveness against infection, symptomatic infection, and infection requiring hospitalisation were between 5 and 100&#xa0;%, 34 and 100&#xa0;%, and 65 and 100&#xa0;% (respectively). No vaccinated HCW deaths were recorded in any study. Pooled estimates of protection against infection, symptomatic infection, and hospitalisation were, respectively, 84.7&#xa0;% (95&#xa0;% CI 72.6-91.5&#xa0;%, <i>p</i>&#xa0;&lt;&#xa0;0.0001), 86.0&#xa0;% (95&#xa0;% CI 67.2&#xa0;%-94.0&#xa0;%; p&#xa0;&lt;&#xa0;0.0001), and 96.1&#xa0;% (95&#xa0;% CI 90.4&#xa0;%-98.4&#xa0;%). Waning protection against infection was reported by four studies, although protection against hospitalisation for severe infection persists for at least 6&#xa0;months post vaccination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Vaccination against SARS-CoV2 in HCWs is protective against infection, symptomatic infection, and hospitalisation. Waning protection is reported but this awaits more mature studies to understand durability more clearly. This study is limited by varying non-pharmacological responses to COVID-19 between included studies, a predominantly female and working age population, and limited information on asymptomatic transmission or long COVID protection.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galgut</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashford</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghataure</LastName><ForeName>Andeep</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Islam</LastName><ForeName>Mimia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sambhi</LastName><ForeName>Tanvir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ker</LastName><ForeName>Yiu Wayn</ForeName><Initials>YW</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Christopher J A</ForeName><Initials>CJA</Initials><AffiliationInfo><Affiliation>Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University, Newcastle, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infection and Tropical Medicine, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Thushan I</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccines and Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, PO Box 273, Fajara, the Gambia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>United Kingdom Health Security Agency, Colindale, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>United Kingdom Health Security Agency, Colindale, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Gastroenterology Unit, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunachie</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NDM Centre For Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vaccine X</MedlineTA><NlmUniqueID>101748769</NlmUniqueID><ISSNLinking>2590-1362</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adenovirus vector</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Healthcare worker</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39221179</ArticleId><ArticleId IdType="pmc">PMC11364133</ArticleId><ArticleId IdType="doi">10.1016/j.jvacx.2024.100546</ArticleId><ArticleId IdType="pii">S2590-1362(24)00119-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lamb Y.N. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81:495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938284</ArticleId><ArticleId IdType="pubmed">33683637</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384:2187&#x2013;2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384:403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahidy F.S., et al. Impact of mRNA vaccines in curtailing SARS-CoV-2 infection and disability leave utilisation among healthcare workers during the COVID-19 pandemic: cross-sectional analysis from a tertiary healthcare system in the Greater Houston metropolitan area. BMJ Open. 2021;11:e054332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8520585</ArticleId><ArticleId IdType="pubmed">34642201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowlkes, A. et al. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance &#x2013; Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep70, 1167&#x2013;1169 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389394</ArticleId><ArticleId IdType="pubmed">34437521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark, A. K. et al. Covid-19 Vaccine Effectiveness in Healthcare Personnel in six Israeli Hospitals (CoVEHPI). medRxiv (2021).</Citation></Reference><Reference><Citation>Haas E.J., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein M., et al. Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020&#x2013;October 2021. Clin Infect Dis. 2022;75:e572&#x2013;e578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8992305</ArticleId><ArticleId IdType="pubmed">35279028</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.H., et al. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Front Immunol. 2022;13(no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8842222</ArticleId><ArticleId IdType="pubmed">35173736</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, J. et al. COVID-19 vaccine &#x2013; Long term immune decline and breakthrough infections. Vaccine39, 6984&#x2013;6989 (11 26).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556595</ArticleId><ArticleId IdType="pubmed">34763949</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen R.J., et al. Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol. 2021;191:1754&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299152</ArticleId><ArticleId IdType="pubmed">34303698</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul, A. C. et al. Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas. medRxiv (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812084</ArticleId><ArticleId IdType="pubmed">35123975</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen P.A., et al. Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston. Texas Am J Pathol. 2022;192:320&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580569</ArticleId><ArticleId IdType="pubmed">34774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Kustin T., et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27:1379&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363499</ArticleId><ArticleId IdType="pubmed">34127854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano K., et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. Nat Commun. 2022;13:5135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9435409</ArticleId><ArticleId IdType="pubmed">36050304</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi L., et al. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718969</ArticleId><ArticleId IdType="pubmed">34954658</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang J., et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022;7:eadd4853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348751</ArticleId><ArticleId IdType="pubmed">35857583</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.J., et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064668</ArticleId><ArticleId IdType="pubmed">33901423</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Noortgate W., L&#xf3;pez-L&#xf3;pez J.A., Mar&#xed;n-Mart&#xed;nez F., S&#xe1;nchez-Meca J. Three-level meta-analysis of dependent effect sizes. Behav Res Methods. 2013;45:576&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">23055166</ArticleId></ArticleIdList></Reference><Reference><Citation>Salika T., Turner R.M., Fisher D., Tierney J.F., White I.R. Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews. BMC Med Res Methodol. 2022;22:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934481</ArticleId><ArticleId IdType="pubmed">35307005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan M.A. The hazards of hazard ratios. Epidemiology. 2010;21:13&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653612</ArticleId><ArticleId IdType="pubmed">20010207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X., Wang W., Liu J., Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A . (R Foundation for Statistical Computing; Vienna, Austria: 2022. Language and Environment for Statistical Computing.</Citation></Reference><Reference><Citation>Posit Team. Rstudio: Integrated Development Environment for R. (Posit Software, PBC, Boston, MA).</Citation></Reference><Reference><Citation>Balduzzi S., R&#xfc;cker G., Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health. 2019;22:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231495</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting Meta-Analyses in R with the ulticen Package. J Stat Soft. 2010;36</Citation></Reference><Reference><Citation>Chico-Sanchez, P. et al. [Effectiveness of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel]. Gaceta Sanitaria36, 484&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8616741</ArticleId><ArticleId IdType="pubmed">34952732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kale P., et al. Vaccine Breakthrough Infections by SARS-CoV-2 Variants after ChAdOx1 nCoV-19 Vaccination in Healthcare Workers. Vaccines. 2022;10(1) (no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778656</ArticleId><ArticleId IdType="pubmed">35062715</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncunill G., et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and &#xa9; healthcare workers. EBioMedicine. 2022;75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752368</ArticleId><ArticleId IdType="pubmed">35032961</ArticleId></ArticleIdList></Reference><Reference><Citation>Poukka, E. et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 &#x2013; October 2021. Vaccine40, 701&#x2013;705 (01 31).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8683266</ArticleId><ArticleId IdType="pubmed">34953607</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen N., et al. Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. Front Med. 2022;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8854655</ArticleId><ArticleId IdType="pubmed">35186963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson K.B., et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021. Post-vaccination SARS-CoV-2 infections and incidence of presumptive B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8344553</ArticleId><ArticleId IdType="pubmed">34137815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp S.A., et al. Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. Sci Rep. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212198</ArticleId><ArticleId IdType="pubmed">35729228</ArticleId></ArticleIdList></Reference><Reference><Citation>Trunfio M., et al. Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: A parallel cohort study in healthcare workers. Vaccines. 2021;9(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8705309</ArticleId><ArticleId IdType="pubmed">34960123</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti E.V., et al. Clinical and Genomic Characterization of SARS CoV-2 infections in mRNA Vaccinated Health Care Personnel in New York City. Clin Infect Dis. 2022;75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9612794</ArticleId><ArticleId IdType="pubmed">34644393</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S., et al. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: a case-control matching study. Clin Infect Dis. 2021;75</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755292</ArticleId><ArticleId IdType="pubmed">34950947</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishya R., et al. Symptomatic post-vaccination SARS-CoV-2 infections in healthcare workers- A ulticentre cohort study. Diabetes Metab Syndr. 2021;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8489275</ArticleId><ArticleId IdType="pubmed">34619430</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassi A., et al. Infection control, occupational and public health measures including mRNA-based vaccination against SARS-CoV-2 infections to protect healthcare workers from variants of concern: A 14-month observational study using surveillance data. PLoS One. 2021;16:e0254920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8284646</ArticleId><ArticleId IdType="pubmed">34270608</ArticleId></ArticleIdList></Reference><Reference><Citation>North C.M., et al. Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19. Clin Infect Dis. 2021;74:1275&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436402</ArticleId><ArticleId IdType="pubmed">34363462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovida F., et al. SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. Nat Commun. 2021;12:6032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521593</ArticleId><ArticleId IdType="pubmed">34654808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivelli A., Fitzpatrick V., Copeland K., Richards J. Factors Associated With COVID-19 Breakthrough Infections in Large Midwestern Healthcare System: Implications for Vulnerable Healthcare Personnel. J Occup Environ Med. 2022;64(8):635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377358</ArticleId><ArticleId IdType="pubmed">35673248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhumal S., et al. SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. Int J Infect Dis. 2022;118:95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8857778</ArticleId><ArticleId IdType="pubmed">35192951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ujjainiya R., et al. High failure rate of ChAdOx1 in healthcare workers during Delta variant surge: A case for continued use of masks post-vaccination. Nat Commun. 2021;13:1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8975928</ArticleId><ArticleId IdType="pubmed">35365648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochuparambil J.J., Issac A. SARS-COV-2 Breakthrough Infections Among the Healthcare Workers Post-vaccination With ChAdOx1 nCoV-19 Vaccine in the South Indian State of Kerala. Clin Pharmacol Drug Dev. 2022;11(Supplement 1):78&#x2013;79.</Citation></Reference><Reference><Citation>Kaur U., et al. Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India. J Med Virol. 2022;94:407&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662184</ArticleId><ArticleId IdType="pubmed">34491572</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo S., et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec. Canada Clinical Infectious Diseases. 2021;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522396</ArticleId><ArticleId IdType="pubmed">34460902</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiani, M. et al. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Euro Surveill26, 04 (4AD).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086247</ArticleId><ArticleId IdType="pubmed">33928898</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz, M. A. et al. Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI). Vaccine40, 512&#x2013;520 (01 24).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8662353</ArticleId><ArticleId IdType="pubmed">34903372</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobel, P. et al. Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. Infect Control Hosp Epidemiol42, 1517&#x2013;1519 (12AD).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280388</ArticleId><ArticleId IdType="pubmed">34167610</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan F.Y., et al. Continued effectiveness of COVID-19 vaccination among urban healthcare workers during delta variant predominance. BMC Infect Dis. 2022;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9097140</ArticleId><ArticleId IdType="pubmed">35549891</ArticleId></ArticleIdList></Reference><Reference><Citation>Larese Filon F., Rui F., Ronchese F., De Michieli P., Negro C. Incidence of COVID-19 infection in hospital workers from March 1, 2020 to May 31, 2021 routinely tested, before and after vaccination with BNT162B2. Sci Rep. 2022;12:2533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847551</ArticleId><ArticleId IdType="pubmed">35169127</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris C., et al. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data. Clin Microbiol Infect. 2021;27(1699):e5&#x2013;1699.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8275842</ArticleId><ArticleId IdType="pubmed">34265462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassi, A. et al. Healthcare worker risk of COVID-19: A 20-month analysis of protective measures from vaccination and beyond (preprint). medRxiv (2021) doi:10.1101/2021.12.02.21267190.</Citation></Reference><Reference><Citation>Swift, M. D. et al. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clin Infect Dis73, e1376&#x2013;e1379 (09 15).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135611</ArticleId><ArticleId IdType="pubmed">33900384</ArticleId></ArticleIdList></Reference><Reference><Citation>Pramod S., et al. Effectiveness of Covishield vaccine in preventing Covid-19 &#x2013; A test-negative case-control study. Vaccine. 2022;40:3294&#x2013;3297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825308</ArticleId><ArticleId IdType="pubmed">35168838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi F.P., et al. BNT162b2 mRNA COVID-19 vaccine effectiveness in the prevention of SARS-CoV-2 infection and symptomatic disease in five-month follow-up: A retrospective cohort study. Vaccines. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8538139</ArticleId><ArticleId IdType="pubmed">34696252</ArticleId></ArticleIdList></Reference><Reference><Citation>Richterman A., et al. Durability of SARS-CoV-2 mRNA Booster Vaccine Protection Against Omicron Among Health Care Workers with a Vaccine Mandate. Clin Infect Dis. 2022;06</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214168</ArticleId><ArticleId IdType="pubmed">35666508</ArticleId></ArticleIdList></Reference><Reference><Citation>Behera P., et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022;18(1) (no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009960</ArticleId><ArticleId IdType="pubmed">35321625</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra S., et al. Effectiveness of BBV152 vaccine against SARS-CoV-2 infections, hospitalizations and deaths among healthcare workers in the setting of high delta variant transmission in New Delhi. India medRxiv. 2022;24</Citation></Reference><Reference><Citation>Marra A.R., et al. Effectiveness of two COVID-19 vaccines (viral vector and inactivated viral vaccine) against SARS-CoV-2 infection in a cohort of healthcare workers. Infect Control Hosp Epidemiol. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9002147</ArticleId><ArticleId IdType="pubmed">35351217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaio, V. et al. COVID-19 vaccine effectiveness among healthcare workers in Portugal: results from a hospital-based cohort study, December 2020 to November 2021. medRxiv.07, (2022).</Citation></Reference><Reference><Citation>Muhsen K., et al. Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study. Clin Infect Dis. 2022;75:e755&#x2013;e763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8675294</ArticleId><ArticleId IdType="pubmed">34698808</ArticleId></ArticleIdList></Reference><Reference><Citation>El Adam S., et al. SARS-CoV-2 mRNA Vaccine Effectiveness in Health Care Workers by Dosing Interval and Time since Vaccination: Test-Negative Design, British Columbia, Canada. Open Forum Infect Dis. 2022;9(5) (no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047244</ArticleId><ArticleId IdType="pubmed">35531384</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugesan M., et al. Protective effect conferred by prior infection and vaccination on COVID-19 in a healthcare worker cohort in South India. PloS ONE [Electronic Resource] 2022;17:e0268797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9122209</ArticleId><ArticleId IdType="pubmed">35594270</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriola C.S., et al. Effectiveness of whole virus COVID-19 vaccine at protecting health care personnel against SARS-CoV-2 infections in Lima. Peru medRxiv. 2022;18</Citation></Reference><Reference><Citation>Hall V., et al. Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. N Engl J Med. 2022;01:1207&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Consonni D., et al. Immunogenicity and effectiveness of BNT162b2 COVID-19 vaccine in a cohort of healthcare workers in Milan (Lombardy Region, Northern Italy) Epidemiol Prev. 2022;46:250&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">36259341</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendola M., et al. COVID-19 impact and vaccine effectiveness among healthcare workers of a large University Hospital in Lombardy. Italy Med Lav. 2021;112:453&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8759047</ArticleId><ArticleId IdType="pubmed">34939623</ArticleId></ArticleIdList></Reference><Reference><Citation>Rifai A., et al. Association Between the Effectiveness and Immunogenicity of Inactivated SARS-CoV2 Vaccine (CoronaVac) with the Presence of Hypertension among Health Care Workers. Clin Exp Hypertens. 2022 doi: 10.1080/10641963.2021.2022687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10641963.2021.2022687</ArticleId><ArticleId IdType="pubmed">34994256</ArticleId></ArticleIdList></Reference><Reference><Citation>Almufty H.B., Mamani M.M.A., Ali A.H., Merza M.A. COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study. J Med Virol. 2022;94(11):5244&#x2013;5250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350230</ArticleId><ArticleId IdType="pubmed">35811398</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti E.V., et al. Effectiveness of MRNA booster vaccine among healthcare workers in New York City during the Omicron surge, December 2021 to January 2022. Clin Microbiol Infect. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9345790</ArticleId><ArticleId IdType="pubmed">35931373</ArticleId></ArticleIdList></Reference><Reference><Citation>Alishaq M., et al. Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. PLoS One. 2021;16:e0258820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8519462</ArticleId><ArticleId IdType="pubmed">34653228</ArticleId></ArticleIdList></Reference><Reference><Citation>Basso P., Negro C., Cegolon L., Larese Filon F. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy) Viruses. 2022;14(2) (no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875653</ArticleId><ArticleId IdType="pubmed">35215930</ArticleId></ArticleIdList></Reference><Reference><Citation>Soegiarto G., et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40(30):4046&#x2013;4056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9135674</ArticleId><ArticleId IdType="pubmed">35660034</ArticleId></ArticleIdList></Reference><Reference><Citation>Anshory M., et al. Factors Associated with Vaccine Breakthrough Incidence among Health Care Workers Vaccinated with Inactivated SARS-CoV-2 Vaccine (CoronaVac) Journal of Research in Health Sciences. 2022;22:e00551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9818040</ArticleId><ArticleId IdType="pubmed">36511263</ArticleId></ArticleIdList></Reference><Reference><Citation>Contractor A., Shivaprakash S., Tiwari A., Setia M.S., Gianchandani T. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin) in healthcare workers in Mumbai, India: A retrospective cohort analysis. PLoS One. 2022;17(10):e0276759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9612509</ArticleId><ArticleId IdType="pubmed">36301977</ArticleId></ArticleIdList></Reference><Reference><Citation>Scobie, H. M. et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status &#x2013; 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep70, 1284&#x2013;1290 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445374</ArticleId><ArticleId IdType="pubmed">34529637</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker H.J., et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. J Infect. 2022;84:675&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8720678</ArticleId><ArticleId IdType="pubmed">34990709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J., et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446717</ArticleId><ArticleId IdType="pubmed">34535466</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary H.R., et al. Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines. Front Med. 2021;8(no pagination)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727751</ArticleId><ArticleId IdType="pubmed">35004746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tre-Hardy, M. et al. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. J Infect83, 559&#x2013;564 (11AD).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380546</ArticleId><ArticleId IdType="pubmed">34437927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N., et al. SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study. J Infect Dis. 2022;01</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903323</ArticleId><ArticleId IdType="pubmed">35104871</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt A.A., Yan P., Shaikh O.S., Mayr F.B., Omer S.B. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population. Clin Infect Dis. 2022;75:e849&#x2013;e856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689859</ArticleId><ArticleId IdType="pubmed">34893812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins R.B., Charles E.J., Mehaffey J.H. Socio-economic status and COVID-19&#x2013;related cases and fatalities. Public Health. 2020;189:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568122</ArticleId><ArticleId IdType="pubmed">33227595</ArticleId></ArticleIdList></Reference><Reference><Citation>The OpenSAFELY Collaborative et al. Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. BMC Med20, 243 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9255436</ArticleId><ArticleId IdType="pubmed">35791013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannick M.S., Gao F., Brown E.R., Janes H.E. Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. Am J Epidemiol. 2023;192:1016&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10505422</ArticleId><ArticleId IdType="pubmed">36883907</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury R., Shah D., Payal A. Healthy worker effect phenomenon: Revisited with emphasis on statistical methods &#x2013; A review. Indian J Occup Environ Med. 2017;21:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763838</ArticleId><ArticleId IdType="pubmed">29391741</ArticleId></ArticleIdList></Reference><Reference><Citation>Oordt-Speets A., et al. Effectiveness of COVID-19 Vaccination on Transmission: A Systematic Review. COVID. 2023;3:1516&#x2013;1527.</Citation></Reference><Reference><Citation>Blomberg B., et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A., et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergolizzi J.V., LeQuang J.A., Magnusson P., Myrcik D., Varrassi G. It&#x2019;s not over till it&#x2019;s over: a narrative review of Long COVID. Signa Vitae. 2021;17:21&#x2013;30.</Citation></Reference><Reference><Citation>Sigfrid L., et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. The Lancet Regional Health &#x2013;. Europe. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Bowe B., Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>